Most promising biomarkers of response to immune checkpoint inhibitors have focused on the expression of the target immune checkpoint protein (in the case of PD-L1/PD-1 inhibitors, expression of PD-L1), the tumor total mutation burden (TMB) as a measurement of neoantigen production, and the ability of the immune system to penetrate the tumor to perform its cytotoxic effects, as measured by the presence of tumor-infiltrating lymphocytes (TILs) [13,14]. This evidence concerns the gene CD274 and neoplasm.